Clinical trial
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775
Study timeline
Study start (actual)2024-10-29Date precision: day
Registry last updated2026-10-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Solid Tumor, Adultunresolved
Metastatic Breast Cancerunresolved
Advanced Breast Cancerunresolved
HER2 Mutation-Related Tumorsunresolved
HER2-positive Metastatic Breast Cancerunresolved
KRAS Mutant Metastatic Colorectal Cancerunresolved
Metastatic Lung Cancerunresolved
Metastatic Colorectal Cancerunresolved
Advanced Lung Cancerunresolved
HER2-positive Advanced Breast Cancerunresolved
Interventions
BBO-10203DRUG
TrastuzumabDRUG · verified · RxNorm: trastuzumab
FulvestrantDRUG · verified · RxNorm: fulvestrant
RibociclibDRUG · verified · RxNorm: ribociclib
FOLFOXDRUG
BevacizumabDRUG · verified · RxNorm: bevacizumab
Sponsors & collaborators
Mapped research locations
New YorkNew York, United States2BostonMassachusetts, United States2DallasTexas, United States2MadridSpain2BarcelonaSpain2São PauloSão Paulo, Brazil2Porto AlegreRio Grande do Sul, Brazil2HoustonTexas, United States1Los AngelesCalifornia, United States1St LouisMissouri, United States1San AntonioTexas, United States1NashvilleTennessee, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06625775 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.